Deoxyribonucleic acid-binding ability of androgen receptors in whole cells: implications for the actions of androgens and antiandrogens by Kuil, C.W. (Cor) & Mulder, E. (Eppo)
Deoxyribonucleic Acid-Binding Ability of Androgen 
Receptors in Whole Cells: Implications for the Action of 
Androgens and Antiandrogens 
COR W. KUIL AND EPPO MULDER 
Department of Endocrinology and Reproduction, Faculty of Medicine and Health Sciences, Erasmus 
University, 3000 DR Rotterdam, The Neth,erlands 
ABSTRACT 
In whole cells, the effects of several androgens and antiandrogens 
on the induction of DNA binding for the human wild-type androgen 
receptor (AR) and a mutant receptor ARL (LNCaP mutation; codon 
868, Thr to Ala) were examined and related to the transcription 
activation ability of these receptors. To study DNA binding, an AR 
expression vector was cotransfected in Chinese hamster ovary cells 
with a promoter interference plasmid cytomegalovirus-(androgen- 
responsive element):,-luciferase, containing one or more androgen- 
responsive elements between the TATA box of the cytomegalovirus 
promoter and the start site of luciferase gene transcription. Expres- 
sion levels of the AR are up-regulated by some agonists, but receptor 
expression levels are comparable for all antiandrogens studied. In the 
presence of androgens, the wild-type AR is able to reduce promoter 
activity of the cytomegalovirus-(androgen-responsive element),-lu- 
ciferase plasmid, indicating androgen-dependent DNA binding of the 
AR. The full antagonists hydroxyflutamide, ICI 176.334, and RU 
23908 block AR binding to DNA. The antagonists cyproterone acetate 
and RU 38486 induce approximately 5O’X of the DNA binding found 
for androgens. In a transcription activation assay, the RU 38486- 
bound receptor was almost inactive, and the receptor complexed with 
cyproterone acetate showed partial agonistic activity. Interaction of 
the antagonists cyproterone acetate, hydroxyflutamide, and RU 
23908 with the mutant receptor ARL resulted in both a DNA-bound 
and a transcriptionally active receptor. 
In conclusion, transformation of the AR to a DNA-binding state in 
whole cells is blocked by several antiandrogens. Furthermore, studies 
with the antiandrogens cyproterone acetate and RU 38486 show that 
DNA binding alone is not sufficient to accomplish full transcriptional 
activity. Full activity requires additional changes, presumably in the 
protein structure of the receptor. (Endocrinology 137: 1870-1877, 
1996) 
T HE ANDROGEN receptor (AR) belongs to a superfamily of ligand-inducible transregulators that includes re- 
ceptors for steroid and thyroid hormones, and vitamins (1). 
As for the other members of the superfamily, molecular 
genetic analysis has identified separable domains responsi- 
ble for DNA binding, hormone binding, and transactivation 
(2, 3). Upon androgen binding, the AR undergoes several 
sequential processes to interact with specialized regions on 
the DNA. These so-called androgen-responsive elements 
(ARES) are commonly located in the regulating regions of 
target genes. Binding of the androgen-bound receptor to its 
response element results in the formation of a stable preini- 
tiation complex that allows efficient transcription initiation 
by RNA polymerase II (4, 5). 
Steroid receptor antagonists inhibit the biological effects of 
agonists, although the precise molecular mechanism(s) of 
these antagonists is unknown. In a model explaining the 
mechanism of antagonist action described recently by 
O’Malley and collaborators (6-B), the importance of a con- 
formational change in the ligand-binding domain is empha- 
sized. The model argues that antagonists recognize regions 
of the ligand-binding domain that result in dimerization and 
DNA binding, but leave the C-terminus of the ligand-binding 
domain in a form still available for protease (6) and antibody 
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recognition (9, 10). As a result, a repressor function is not 
removed, and the receptor is not able to induce transcription. 
In accordance with this model, binding of RU 38486 to an irl 
z~ifr~ translated AR, resulted in both protease digestion of the 
C-terminus of the ligand-binding domain (11, 12) and dis- 
sociation of the heat shock protein-receptor complex (12). 
Other results suggested that more steps could be involved in 
the mechanism of antiandrogen action; upon binding of the 
AR antagonists cyproterone acetate, hydroxyflutamide, ICI 
176.334, or RU 23908, no indications were found for involve- 
ment of the C-terminus of the AR in the mechanism of an- 
tiandrogen action (12, 13). As an intact heat shock protein- 
receptor complex is still present upon binding of these 
antiandrogens in Gfro (12), we hypothesized that dissociation 
of the receptor from this complex and subsequent binding of 
the receptor to DNA, would be blocked partly or completely 
by some antiandrogens within intact cells. Dissociation of the 
oligomeric receptor complex and subsequent binding of the 
receptor to DNA have previously been proposed to be im- 
paired by antagonists (14-16). However, recent observations 
of DNA-bound receptors do not favor these steps as critical 
for the actions of antiprogestagens and antiestrogens (17-21). 
To find experimental support for the inhibition of DNA 
binding by several antiandrogens, we applied a promoter 
interference assay, described by Reese and Katzenellenbogen 
for the estrogen receptor (17). This assay makes it possible to 
examine the effects of ligands, both hormones and antihor- 
mones, on AR binding to DNA within mammalian cells. The 
promoter interference assay uses the principle of steric hin- 
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drance between the AR and basal transcription factors on a 
constitutive [cytomegalovirus (CMV)] promoter. Further- 
more, the binding of the AR to DNA was related to the 
transactivation capacity of the various ligand-receptor com- 
plexes. The mutant receptor ARL (mutation in codon 868; Thr 
to Ala) was also investigated, as binding of several antian- 
drogens resulted in an active receptor complex for this mu- 
tant. 
Materials and Methods 
Materials 
R1881 (methyltrienolone) was purchased from New England Nuclear 
Corp. (Boston, MA). RU 38486 (mifepristone) and RU 23908 (nilutamidc) 
were gifts from Roussel-UCLAF (Paris, France), cyproterone acetate was 
obtained from Schering (Berlin, Germany), hydroxyflutamide was ob- 
tained from Schering (Bloomfield, NJ), and ICI 176.334 (Casodex) was 
obtained from ICI Pharmaceuticals (Macclesfield, UK). All other steroids 
were purchased from Steraloids (Wilton, NH). The BM chemilumines- 
cence Western blotting kit was obtained from Boehringer Mannheim 
(Mannheim, Germany). The plasmids pcDNA1 and pCL2 were obtained 
from Invitrogen (San Diego, CA) and Promegn (Madison, WI), respec- 
tively. The mouse mammary tumor virus-luciferase (MMTV-LUC) re- 
porter plasmid was kindly provided by Organon (Oss, The Nether- 
lands). 
Preparation of AR and reporter plasmids 
Preparation of the MMTV-LUC reporter plasmid (22) and the ex- 
pression plasmids for the wild-type human AR (encoding an AR of 910 
amino acids) (23), mutant ARL (LNCaI’mutation; codon 868, Thr to Ala) 
(24), and mutant AR64 (codon 567, Cys to Ser, and codon 570, Cys to I’he) 
(25) have been described previously. The CMV-LUC plasmid was con- 
structed by cloning a SncI-BnrrrHI fragment that spanned the luciferase 
transcription unit from pGL2 into pcDNA1 (a plasmid containing the 
CMV promoter), which had been digested with SncI and BarrrHI. CMV- 
(ARE), ,-LUC promoter interference plasmids (containing one to three 
androgen-responsive elements) were prepared by ligation of double 
stranded oligonucleotides containing a consensus ARE (GGTACAgtt- 
TGTTCT) (26) into the SncI site of the CMV-LUC plasmid. 
Cell culture and transfections 
Chinese hamster ovary (CHO) cells were maintained in DMEM- 
Ham’s F-12 tissue culture medium supplemented with 5% charcoal 
dextran-treated FCS. For promoter interference assay, CHO cells were 
plated at 1.5 X 1Oi cells/well (10 cm’), grown for 24 h, and transfected 
&ernight by calcium phosphate precipytation, as described previously 
(27). Cells were transfected with 75 nr expression ulasmid, encoding AR, 
ARL, or AR64, and 7.5 ng CMV-LU? o; CMV-(ARE),-,-LUC plaimid. 
Carrier DNA (pTZ19) was added in each case to a total of 5 pg/ well. For 
transcription regulation studies, CHO cells were plated at 0.6 X lo5 
cells/well (4 cmz) and transfected with 10 ng AR or ARL expression 
plasmid, 200 ng MMTV-LUC reporter plasmid, and 1.8 fig pTZ19/ well. 
After transfection, the cells were washed, and experimental media were 
added. Upon an incubation period of 24 h, cells were harvested for the 
LUC assay, as described previously (12). 
Western immunoblot analysis 
Whole cell lysate was prepared by resuspending the cell pellet from 
a well (10 cm’) in 200 ul 40 rnM Tris-HCI (DH 7.41. 1 rnM EDTA. 10% 
(vol/ ~31) glyc&ol, l’b’(vol /vol) Triton X-i’O0, 0.5% (wt/ vol) sodium 
deoxycholate, 0.08% (wt/vol) SDS, 0.6 rnhl phenylmethylsulfonylfluo- 
ride, and 0.5 mbi bacitracin at 4 C. The lysate was centrifuged (10 min; 
1700 X ,y), and 20 ~1 of the supernatant were used for Western immu- 
noblot analysis, essentially as described previously (27). The polyclonal 
rabbit antiserum SP197, recognizing the AR (epitope: amino acids l-20) 
(28) \vas used as the primary antibody in a chemiluminescence protein 
detection method, performed as described by the manufacturer (Boehr- 
inger Mannheim). 
Results 
Transcription activation studies of wild-type AR and 
mutant ARL in CHO cells 
To compare DNA binding of the AR with effects on tran- 
scription activation, both an in zk DNA binding assay (de- 
scribed in the next section) and a transcription activation 
assay were used. Either wild-type AR or mutant ARL ex- 
pression plasmids were transiently transfected into CHO 
cells together with the AR-sensitive reporter plasmid 
MMTV-LUC. The mutant receptor ARL contains a mutation 
in the ligand-binding domain (amino acid 868, Thr replaced 
by Ala) that leads to a decrease in steroid binding specificity 
(24). The ligands, both androgens and antiandrogens, differ 
in their binding affinities for the AR (24,27,29,30); therefore, 
added concentrations of ligand were standardized accord- 
ingly. The nonmetabolizable synthetic androgen R1881 (1 
nM) and the natural androgens dihydrotestosterone (1 nM) 
and testosterone (10 nM) induced LUC activity to the same 
level (Fig. 1A) and in a dose-dependent manner (results 
shown for R1881 in Fig. 3). LUC activities induced by 100 IIM 
of the steroidal antihormones cyproterone acetate and RU 
38486 were approximately 55% and 15% of that observed 
with 1 nM R1881. [RU 38486 has antiandrogenic properties, 
besides its effect as an antiprogestagen / antiglucocorticoid 
(31, 32).] Partial agonistic activity was not observed for the 
nonsteroidal antiandrogens hydroxyflutamide, ICI 176.334, 
and RU 23908 (used in concentrations up to 1 PM). All an- 
tiandrogens inhibited the LUC activity induced by 0.1 11~ 
R1881 (Fig. 1B). In contrast, in cells with the mutant receptor 
ARL, cyproterone acetate and hydroxyflutamide induced 
LUC activity to the same level as that observed with R1881, 
dihydrotestosterone, and testosterone (Fig. 1C). Some partial 
agonistic activity of RU 23908 on ARL was found, whereas 
RU 38486 and ICI 176.334 did not activate ARL. The lack of 
agonistic activity of RU 38486 and ICI 176.334 was not due 
to the absence of binding to the mutant ARL, as LUC activity 
induced by 0.1 nM R1881 could be inhibited with both an- 
tihormones (Fig. 1D). CHO cells contain a limited amount of 
glucocorticoid receptors, and RU 38486 is able to bind to 
these receptors. However, the effect of RU 38486 on tran- 
scription activation was not due to this receptor system; in 
the absence of AR or ARL expression vectors, RU 38486 failed 
to induce LUC activity from the transfected MMTV-LUC 
reporter plasmid (not shown). 
Promoter activity of constructs containing multiple ARES 
DNA binding of the estrogen receptor in whole cells was 
studied previously by Reese and Katzenellenbogen (17) with 
a promoter interference assay, based on the principle of steric 
hindrance between a transcription factor and basal transcrip- 
tion factors on a constitutively active promoter. In the present 
study, an AR-dependent promoter interference reporter 
plasmid was constructed by inserting consensus ARES (26) 
into the SncI site that lies between the TATA box of the 
constitutively active CMV promoter and the start site of 
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FIG. 1. Transcriptional activity of the 
wild-type AR and LNCaP AR CARL) in 
the presence of androgens and antian- 
drogens. LUC expression was deter- 
mined in CHO cells transiently cotrans- 
fected with AR (A and B) or ARL (C and 
D) expression plasmids and the re- 
porter plasmid MMTV-LUC. A and C, 
After transfection, cells were incubated 
without hormone (PH) or with R1881(1 
nM), dihydrotestosterone (DHT; 1 nM), 
testosterone (T; 10 nM), cyproterone ac- 
etate (CPA; 100 nM), RU 38486 (RU486; 
100 nM), hydroxyflutamide (OH-F; 1 
FM), ICI 176.334 (ICI334; 1 FM), or RU 
23908 (RU908; 1 FM) for 24 h. LUC ac- 
tivity in the presence of 1 nM R1881 was 
set at 100%. Values are the mean 
c-t SEM) of three or four determinations; 
each determination was performed in 
triplicate. B and D, For competition 
studies, the various antiandrogens 
were added simultaneously with 0.1 nM 
R1881. The second bar shows the activ- 
ity of 0.1 nM R1881 alone (set as 100%). 
Values are the mean (*SEMI of three 
determinations. 
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transcription of the messenger RNA, encoding the luciferase 
protein. Binding of AR at that position should hinder the 
assembly of the transcription initiation complex and hence 
reduce the expression of the LUC gene. The functionality of 
the CMV-(ARE),,-,-LUC plasmids was verified by cotrans- 
fection of the construct with the expression vector for the 
wild-type AR into CHO cells. The promoter activity was 
reduced in all ARE-containing promoter interference plas- 
mids in the presence of R1881, whereas no influence on LUC 
expression was seen in cells cotransfected with the original 
CMV-LUC plasmid (Fig. 2A). The down-regulation of pro- 
moter activity was dependent on the number of inserts; it was 
the largest with the CMV-(ARE),-LUC plasmid (remaining 
activity compared to control, 47%). In the absence of hor- 
mone, no differences in LUC activity between the different 
reporter plasmids were observed. 
Overexpression of a transcription factor could sequester 
other factors necessary for the transcriptional activity of a 
promoter (i.e. squelching) (33). As squelching does not re- 
quire specific DNA binding or an intact DNA-binding do- 
main, the receptor mutant AR64 was studied to further verify 
that the reduction in promoter activity was actually due to 
DNA binding of the AR to the CMV-(ARE),-LUC plasmid. 
In this receptor mutant, the structure of the first zinc cluster 
is disrupted by the replacement of two of the four cysteine 
residues. Mutagenesis experiments have shown that these 
cysteine residues are essential for DNA-binding capacity of 
the receptor (34). No effect on LUC expression was seen, 
when CMV-(ARE),-LUC plasmid was cotransfected with the 
AR64 expression plasmid in CHO cells in the presence of 
ligand (Fig. 2B). As expression levels of wild-type AR and 
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mutant AR64 were comparable, as analyzed by Western blot- 
ting (Fig. 2C), a squelching phenomenon could not account 
for the repression of the promoter activity in the CMV- 
(ARE),-LUC plasmid. (The effect of ligand on AR expression 
level is discussed further in the section AX expression levels 
and miqation pattern below.) 
To exclude an effect on promoter activity due to a limited 
amount of glucocorticoid receptor in CHO cells, we also 
examined the effect of R1881 and dexamethasone on cells 
transfected only with either the CMV-LUC or the CMV- 
(ARE),-LUC plasmid. In the absence of AR expression plas- 
mid, no reduction of LUC expression from both plasmids 
could be demonstrated either in the presence of 1 nM R1881 
or 100 nM dexamethasone (result shown for R1881; Fig. 28). 
In summary, the results presented in Fig. 2, show that 
interference with promoter activity is dependent on the pres- 
ence of ARES in the reporter plasmid, a functional AR, and 
the androgen R1881. This permits the conclusion that the 
LUC activity measured with this assay system reflects DNA 
binding of the AR in whole cells. 
Comparison of transcription activation and DNA-binding 
ability of AR 
In the previous sections, we reported that the complex of 
androgen and receptor both activated transcription from a 
MMTV-LUC plasmid and interfered with the constitutively 
active CMV promoter. To investigate the dose dependency 
of the ligand in both processes, we determined the dose- 
response curves of R1881 in both assays. Maximal effects of 
the AR on both transcription activation and promoter inter- 
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FIG. 2. Effects of multiple ARES and different receptors on CMV 
promoter activity. A, CHO cells were cotransfected with AR expres- 
sion plasmid and the CMV-LUC construct containing zero to three 
ARES. After transfection, cells were treated with control vehicle or 1 
nM R1881. Control values were determined as LUC activity in cells 
transfected with each CMV-(ARE),-,-LUC construct and AR expres- 
sion vector in the absence of ligand and were set at 100%. Data 
represent the mean ( ~SEM) of four to six determinations; each deter- 
mination was performed in triplicate. B, Promoter activity of CMV- 
LUC and CMV-(ARE),-LUC plasmid, cotransfected in CHO cells 
without or with the expression plasmids for wild-type AR or mutant 
AR64 (mutations in DNA-binding domain; codons 567 and 570, Cys 
to Ser) as indicated on the x-axis. Cells were treated with control 
vehicle or 1 nM R1881, and LUC activity was measured. Control 
values were determined as described in A, whereas the results are the 
mean (~SEM) of five to six determinations. C, Western blot analysis 
of lysates from cells, transfected with wild-type AR or the mutant 
AR64 and incubated with or without 1 nM R1881. Whole cell lysates 
were fractionated with gel electrophoresis, and separated proteins 
were transferred to nitrocellulose and visualized with a chemilumi- 
nescence protein detection method, using the AR-specific polyclonal 
antiserum SP197 as primary antibody. Molecular mass markers (kilo- 
daltons) were run on a parallel lane, and their positions are indicated 
on the right of the blot. 
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FIG. 3. Effect of R1881 concentration on the promoter activity of the 
CMV-(ARE),-LUC plasmid. The CMV-(ARE),-LUC promoter inter- 
ference plasmid was cotransfected with the AR expression plasmid in 
CHO cells, and increasing concentrations of R1881 were added (0). 
Inhibition of promoter activity in the presence of 1 nM R1881 was set 
at 100%. The effect of the R1881 concentration on transcription ac- 
tivation of the MMTV-LUC reporter plasmid in transfected CHO cells 
is also shown (0). Transcription activation in the presence of 1 nM 
R1881 was set at 100%. The data are the mean of two or three 
determinations (~sEM). 
ference were reached at 1 nM R1881 and set at 100% activation 
or inhibition, respectively. The dose-response curve of R1881 
on transcription activation matched the effect of R1881 on 
promoter interference (Fig. 3). Because promoter interference 
in this assay system reflects DNA binding of the AR, these 
results also indicate a direct correlation between the percent 
DNA binding and transcription activation. 
Influence of different hormones and antihormones on DNA- 
binding ability of AR 
The promoter interference assay permits the study of DNA 
binding of the receptor in whole cells. Therefore, we exam- 
ined the effects of several hormones and antihormones on 
their ability to reduce promoter activity of the CMV-(ARE),- 
LUC plasmid in the presence of either the wild-type AR or 
the mutant ARL. Neither receptor interacted with the pro- 
moter interference construct in the absence of R1881, and 
treatment with R1881(1 nM) resulted in a similar decrease (to 
50%) of LUC activity. This implies a similar dependence on 
the ligand R1881 for DNA binding of both the AR and ARL 
to the ARES in the promoter interference construct. CHO cells 
exposed to the natural androgens dihydrotestosterone (1 nM) 
and testosterone (10 nM) displayed a comparable reduction 
in the promoter activity of the CMV-(ARE),-LUC plasmid, as 
found with 1 nM R1881 (defined as 100% inhibition; Fig. 4, 
A and B). Cells expressing the wild-type AR and incubated 
with the antagonists cyproterone acetate (100 nM) and RU 
38486 (100 nM) also showed promoter interference, although 
less than that in the presence of androgens (Fig. 4A). The 
complete antagonists hydroxyflutamide (1 PM), ICI 176.334 
(1 PM), and RU 23908 (1 FM) only slightly affected the pro- 
moter activity of the reporter plasmid (Fig. 4A). For the 
mutant receptor ARL, binding of cyproterone acetate, hy- 
droxyflutamide, and RU 23908 resulted in a comparable re- 
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FIG. 4. Promoter interference of the wild-type AR and mutant re- 
ceptor ARL in the presence of several androgens and antiandrogens. 
CHO cells were cotransfected with CMV-(ARE),-LUC promoter in- 
terference plasmid and wild-type AR or mutant ARL expression plas- 
mid, and incubated without hormone (pH) or with 1 nM R1881,l nM 
dihydrotestosterone (DHT), 10 nM testosterone (T), 100 nM cyprot- 
erone acetate (CA), 100 nM RU 38486 (RU486), 1 /.J,M hydroxyflut- 
amide (OH-F), 1 FM ICI 176.334 (ICI334), or 1 PM RU 23908 (RU908). 
Inhibition of promoter activity in the presence of 1 nM R1881 was set 
at 100%. Values are the mean ( SEM) of four or five determinations. 
duction of LUC activity of the CMV-(ARE),-LUC plasmid as 
observed for the androgens (Fig. 4B). The full antagonist ICI 
176.334 showed only a minor effect with the mutant ARL, 
resembling its effect on the wild-type receptor. For the RU 
38486-bound ARL, a slightly smaller reduction in promoter 
activity was observed than that for the wild-type receptor. 
The results on transcription activation and promoter in- 
terference of both wild-type AR and mutant ARL, complexed 
with different ligands, are summarized in Table 1. A corre- 
lation between DNA binding and transcription activation 
was observed for most compounds, with the exception of RU 
38486. 
AR expression levels and migration pattern 
As hormone addition was shown to have effects on the 
receptor stability (29) and phosphorylation status of the re- 
ceptor (37), we wanted to exclude the possibility that the 
differences in the promoter interference assay were due to 
differences in receptor expression levels. Therefore, extracts 
were prepared from transfected cells after treatment with the 
various ligands, and receptors were analyzed by Western 
blotting. In the absence of hormone, the wild-type receptor 
and the mutant receptor AR64 migrated as two protein bands 
(110-112 kDa; Fig. 2C). The difference in electrophoretic 
mobility represents differences in the degree of phosphor- 
ylation of the receptor (35-37). An additional decrease in the 
electrophoretic mobility of the receptor protein was ob- 
TABLE 1. Summary of the effects of ligands on the wild-type and 
mutated receptors 
AR ARL 
DNA Trans-activation DNA Trams-actlvatlon 
binding binding 
Androgen ++ ++ ++ ++ 
CPA + + ++ ++ 
RU486 + + - 
OH-F - - ++ ++ 
ICI334 - - 
RU908 - - ++ + 
p, No effect; +, limited effect; + +, full effect; CPA, cyproterone 
acetate; RU486, RU 38486; OH-F, hydroxyflutamide; IC1334, ICI 
176.334; RU908, RU 23908. 
ARL 
-116 
FIG. 5. Effect of androgens and antiandrogens on expression levels of 
wild-type AR and mutant ARL. Western blot analysis of lysates from 
CHO cells, transfected with either AR or ARL expression plasmid and 
incubated with the ligands, as described in Fig. 4. Whole cell lysates 
were fractionated with gel electrophoresis, and separated proteins 
transferred to nitrocellulose and visualized with a chemilumines- 
cence detection method, using the AR-specific polyclonal antiserum 
SP197 as primary antibody. Molecular mass markers (kilodaltons) 
were run on a parallel lane, and their positions are indicated on the 
right of each blot. 
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served, when CHO cells, expressing the wild-type AR, were 
incubated in the presence of R1881 (Fig. 2C). These results are 
in agreement with observations described by others (37) and 
suggest the appearance of an additional protein form in the 
presence of R1881. The additional decrease in electrophoretic 
mobility was not observed for the mutant receptor AR64 in 
the presence of R1881 (Fig. 2C) (37). The expression levels of 
wild-type receptor (Fig. 5A) and mutant ARL (Fig. 5B) also 
increased in the presence of the natural androgens dihy- 
drotestosterone and testosterone. In contrast, binding of an- 
tagonists to both receptors, even those antagonists that 
showed agonist activity with ARL, did not affect receptor 
expression levels (Fig. 5, A and B). This indicates that for all 
antiandrogens studied, the receptor expression levels were 
comparable, and variations in promoter interference be- 
tween the various antiandrogen-bound receptors could not 
be explained by differences in receptor expression levels. 
Discussion 
An essential step in androgen action is transformation of 
the AR from a complex with heat shock proteins (27) to a 
DNA-binding state. DNA binding of full-length AR has been 
studied previously by in vitro electrophoretic mobility shift 
assays with oligonucleotidcs containing a consensus ARE. In 
these studies, performed with wild-type AR produced in a 
variety of systems (ill vitro transcription/ translation, tran- 
siently transfected COS-7 cells, or recombinant baculovirus- 
infected Sf9 cells), DNA binding of the receptor was either 
hormone independent (13, 38, 39) or required intracellular 
hormone exposure (40, 41). Demonstration of hormone-de- 
pendent DNA binding in the electrophoretic mobility shift 
assay is complicated by the isolation procedure of the AR 
protein, which may cause artificial receptor activation. In 
addition, the results of in ilitro studies generally do not ac- 
count for receptor-ARE interactions under equilibrium con- 
ditions. In the present study, we used a promoter interfer- 
ence assay that permits study of AR interaction with DNA 
in whole cells. 
The promoter interference assay was originally described 
by Hu and Davidson (42), who used it to show that lnc 
repressor, bound to its operator near a transcription initiation 
site, strongly repressed the activity of a reporter gene. This 
same principle, also used to study interaction of estrogen 
receptor with DNA (17), was applied by us to examine DNA 
binding of the AR in whole cells. In these studies, with a 
promoter interference CMV-(ARE),-LUC construct trans- 
fected into CHO cells, it was shown that reduced LUC ac- 
tivity resulted from inhibition of transcription due to andro- 
gen-dependent binding of the AR to its response elements. 
First, interference of CMV promoter activity was dependent 
on the presence of ARES in the reporter construct; second, on 
the expression of functional receptors; and third, on the ad- 
dition of androgens. Furthermore, we observed reduced 
LUC activity in transiently transfected CHO cells at AR con- 
centrations that were functional within the cells; the amounts 
of AR expression plasmid nccdcd to suppress LUC activity 
from the promoter interference plasmid were comparable to 
those necessary to activate transcription from a MMTV-LUC 
reporter plasmid. In addition, we could exclude that the 
decrease in LUC activity was due to squelching, a phenom- 
enon that has been shown to occur at high expression levels 
of steroid receptors (43). 
The observation that the AR is unable, in the absence of 
ligand, to bind to ARES in the CMV-(ARE),-LUC reporter 
plasmid is in agreement with results from studies that 
showed that the unliganded forms of the progesterone (16, 
44), glucocorticoid (45), and androgen (40, 41) receptors are 
unable to bind to their response elements on DNA. The 
androgen-dependent binding of the AR to DNA, as observed 
in the present study, supports a model in which binding of 
the ligand to the receptor causes dissociation of the heat 
shock protein-receptor complex and exposes the major 
dimerization region of the receptor. This enables the ligan- 
ded receptor to dimerize and bind with high affinity to its 
response element. These structural changes and related co- 
valent modifications enable the bound receptor to function 
as a ligand-dependent transcription activator [reviewed by 
Tsai and O’Malley (S)]. Results from other studies performed 
on progesterone (20) and estrogen (17, 21) receptors do not 
support this model. These observations indicate that pro- 
gesterone and estrogen receptors are capable of binding to 
DNA within whole cells in the absence of ligand and that the 
ligand is needed to enhance or stabilize the interaction of the 
receptor with response elements. We feel that the differences 
with respect to hormone dependency of DNA binding be- 
tween androgen and glucocorticoid receptors, on the one 
hand, and the estrogen receptor, on the other, may warrant 
some caution of generalization of steroid hormone receptor 
transformation from an inactive toward an active state. 
The inability of AR antagonists to induce DNA binding of 
the receptor has been postulated as one of the molecular 
mechanisms of antiandrogen action (27, 40). The full antag- 
onists, hydroxyflutamide, ICI 176.334, and RU 23908, which 
lack agonist activity [previously shown (12, 24, and 29)], 
failed to induce DNA binding of the wild-type AR in whole 
cells. The antagonistic activity of these compounds stems, 
therefore, from their inability to induce DNA binding of the 
receptor. Presumably, these compounds are unable to induce 
the necessary changes in the conformation of the AR to 
release the associated proteins (12). The antihormone-recep- 
tor complexes formed with cyproterone acetate and RU 
38486 were capable of binding to DNA within the cell. RU 
38486, which was transcriptionally almost inactive, reduced 
promoter activity in the promoter interference assay to the 
same extent as the partial agonist cyproterone acetate, indi- 
cating that DNA binding is a prerequisite for trnlls-activation, 
but that DNA binding alone is not sufficient to ensure a 
transcriptionally active receptor. ARs, when associated with 
RU 38486, bind to their responsive elements in whole cells 
and ir7 zifro (40). However, RU 38486 apparently induces an 
altered conformation of the C-terminus of the receptor com- 
pared to the agonist-induced conformation, reflected by dif- 
ferences in proteolytic digestion pattern (11, 12), migration 
on sucrose gradients (12), and electrophoretic mobility shift 
assays (40). Similar observations were made in studies with 
the RU 38486-bound progesterone receptor (6, 9, 10, 18, 20, 
46, 47). Therefore, the failure of the antagonist RU 38486 to 
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trolls-activate is due to structural alterations in the ligand- 
binding domain. 
The progesterone and estrogen receptor antagonists have 
been tentatively divided into two classes depending on their 
level of action (48, 49). The so-called type I antagonists in- 
terfere with binding of the receptor to DNA. The other class 
of antagonists (type II; including, for example, RU 38486) (48) 
induces stable, high affinity DNA binding of the receptor, but 
blocks the interaction of the receptor with the transcription 
initiation complex. Recently, McDonnell ct nl. (50) distin- 
guished the estrogen receptor agonists from partial agonists 
on the bases of molecular criteria. Additionally, a classifica- 
tion of the known estrogen receptor antagonists into three 
distinct classes was proposed. These researchers hypothe- 
sized that the estrogen receptor might exist in the cell in 
multiple conformations, representing the inactive state, the 
active state, and several intermediate states. Antagonists ex- 
ert their action by stabilizing a specific structure. These dis- 
tinct conformations could result as a consequence of the 
ability of these compounds to keep the receptor in a specific 
conformation by blocking a progressive change from inactive 
to active. The effects of AR agonists and antagonists in our 
analysis suggest that the antiandrogens also promote stabi- 
lization of several different conformations. As a conse- 
quence, the known AR antagonists can be classified into 
three distinct categories. When we adopt the convention 
established by Klein-Hitpass et nl. (48), the compounds hy- 
droxyflutamide, ICI 176.334, and RU 23908 are type I antag- 
onists, blocking the process that leads to DNA binding. We 
propose to add a further classification of the type II antian- 
drogens in two subtypes: the C-terminal end of the receptor 
is either involved (type IIa) or not involved (type IIb) in the 
mechanism of antagonist action. According to this classifi- 
cation, RU 38486 is a type IIa antagonist that induces an 
incorrect conformational change at the C-terminus of the 
ligand-binding domain of the AR (11, 12). Cyproterone ac- 
etate represents a type IIb antagonist that stabilizes the AR 
in a conformation that allows it to exhibit some transcrip- 
tional activity. Protease sensitivity studies did not reveal an 
abnormal conformation for the C-terminal part of the ligand- 
binding domain after binding of this ligand (12). 
For the mutant receptor ARL, some antiandrogens should 
be classified differently. RU 23908 induced DNA binding of 
ARL without the exhibition of full agonistic activity. As the 
C-terminus of the ligand-binding domain is not involved in 
its antagonistic behavior (12), this compound represents a 
type IIb antagonist for ARL. Hydroxyflutamide and cypro- 
terone acetate are full agonists for ARL. It could be specu- 
lated that the single amino acid change in the mutant ARL 
contributed to the ligand-induced changes in ARL confor- 
mation that potentiated transactivation (with cyproterone 
acetate), DNA binding (with RU 23908), or both (with hy- 
droxyflutamide). 
In conclusion, transformation of the wild-type AR to a 
DNA-binding state in whole cells is blocked by several an- 
tiandrogens (hydroxyflutamide, ICI 176.334, and RU 23908). 
Although DNA binding is a necessary step to accomplish 
transcriptional activity, studies with another antiandrogen 
(RU 38486) show that DNA binding alone is not sufficient; 
full transcriptional activity requires additional changes, pre- 
sumably in the protein structure of the receptor. The classi- 
fication of AR antagonists into several types according to the 
site of action, as discussed above, might be useful for the 
development of new compounds for clinical use. 
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